HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Shenzhen Chipscreen Bioscience / Equity Bottom-Up

<ul>
<li>The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain. </li>
<li>The continuous large investment in R&amp;D, high selling expenses, and declining R&amp;D expending capitalization would further drag down profitability.</li>
<li>So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.</li>
</ul>


The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain. 
The continuous large investment in R&amp;D, high selling expenses, and declining R&amp;D expending capitalization would further drag down profitability.
So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.


Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Index Rebalance

<ul>
<li>The main question, for yet another rebalance, is whether the index committee chooses a 6 month minimum listing history or increases it to 12 months in line with the methodology.</li>
<li>That decision will result in either 4 or 5 changes at the rebalance. The deletions remain the same, while there is only 1 inclusion common across both lists.</li>
<li>There is a fair bit to trade on the potential inclusions and exclusions and we expect the inclusions to outperform the deletions over the next couple of months.</li>
</ul>


The main question, for yet another rebalance, is whether the index committee chooses a 6 month minimum listing history or increases it to 12 months in line with the methodology.
That decision will result in either 4 or 5 changes at the rebalance. The deletions remain the same, while there is only 1 inclusion common across both lists.
There is a fair bit to trade on the potential inclusions and exclusions and we expect the inclusions to outperform the deletions over the next couple of months.


STAR50 Index Rebalance Preview (March 2022): What Will The Index Committee Do?

China

Shenzhen Chipscreen Biosciences Co., Ltd. operates as a drug development company. The Company produces and sells anticancer drugs, immunological disease therapeutic drugs, metabolic disease therapeutic drugs, and other products. Shenzhen Chipscreen Biosciences markets its products throughout China.

Shenzhen Chipscreen Bioscience (688321 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shenzhen Chipscreen Bioscience (688321 CH)

Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities

This insight analyzed Chipscreen Biosciences about its key products/candidates, small market space of PTCL, fierce competition, single product...

Xinyao (Criss) Wang

STAR50 Index Rebalance Preview (March 2022): What Will The Index Committee Do?

There could be 4 or 5 changes to the STAR50 Index at the March rebalance depending on whether the index committee uses a 6 month or 12 month...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)